MONROE TOWNSHIP, N.J., Oct. 16, 2020 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, announced today the FDA approval of its new CardioGen-82 infusion system to enhance automation, efficiency and simplicity in cardiac position emission tomography (PET) myocardial perfusion imaging (MPI). This next-generation infusion system model will replace the company's current infusion system.
Vittorio Puppo, President and CEO of Bracco Diagnostics Inc. said, "The new infusion system exemplifies Bracco's significant investment in the cardiac PET imaging modality and is the culmination of thoughtful design and feedback from healthcare providers. Developing innovative products that support clinicians in diagnosing coronary artery disease is our commitment to the patients we serve."
Designed for efficiency, flexibility, and ease of use
Numed, a well established company in business since 1975 provides a wide range of service options including time & material service, PM only contracts, full service contracts, labor only contracts & system relocation. Call 800 96 Numed for more info.
Developed with clinicians and nuclear medicine technologists in mind, the new infusion system is elegantly designed with intuitive and ergonomic details that provide easy access to all system components while minimizing radiation exposure for staff and patients.
Other smart features enable workflow efficiencies that can save nearly an hour at the beginning of each day of patient imaging and eliminate manual record keeping. A choice of dosing options and other protocol parameters make changes in scheduling and patient needs easy to accommodate.
Bracco's commitment to excellence in cardiac PET imaging
"Cardiac PET MPI with the CardioGen-82 generator has helped accurately diagnose thousands of patients since 1989," said Kim McDaniel, Senior Director, Nuclear Medicine Sales and Market Support. "Bracco was the first company to heavily invest in the modality for the diagnosis of coronary artery disease, and our introduction of the new infusion system is one more example of our commitment to our customers and patients worldwide."
Indications and Usage for CARDIOGEN-82® (Rubidium Rb 82 Generator)
CARDIOGEN-82® (Rubidium Rb 82 Generator) is a closed system used to produce rubidium Rb 82 chloride injection for intravenous administration. Rubidium Rb 82 chloride injection is a radioactive diagnostic agent indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected or existing coronary artery disease.